Boston Keratoprosthesis Type 1

Muzychuk, Adam; Robert, Marie-Claude; Dao, Stanley; Harissi‐Dagher, Mona

doi:10.1016/j.ophtha.2016.07.019

Cited by 16 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of frozen carrier grafts offers similar clinical outcomes with no differences in device retention, visual rehabilitation, or rates of complications when compared to fresh corneal donors. 92 Furthermore, the sterilization technique by gamma ray radiation has been successfully used as carrier for both BKPro and fresh cornea as well, allowing long-time storage and easy transport at room temperature. 93 Additionally, xenograft transplantation, limited in the past due to risk of graft failure, host immune reaction and cross-species diseases has recently found a renewed interest.…”

Section: Future Of Bkpromentioning

confidence: 99%

<p>Boston Type 1 Keratoprosthesis: Updated Perspectives</p>

Nonpassopon¹,

Niparugs²,

Cortina³

2020

OPTH

View full text Add to dashboard Cite

The use of Boston type 1 keratoprosthesis (BKPro) has significantly increased worldwide. It is no longer considered a procedure of last resort but a reasonable option for patients with otherwise poor prognosis for a traditional penetrating keratoplasty. BKPro was approved by the Food and Drug Administration in 1992 for bilateral severe corneal blindness due to multiple corneal transplant failure. Over the years, indications have extended beyond recurrent immunologic rejection to include other conditions such as chemical injury and other causes of bilateral limbal stem cell deficiency, extensive corneal neovascularization, neurotrophic corneas and hypotony, among others. Numerous advances in the design of the BKPro, improvement of preoperative, intraoperative and postoperative management have resulted in favorable outcomes and a reduction in postoperative complications. Accordingly, many studies have shown that implantation of this device is highly effective in restoring vision with very good short-term outcomes. However, due to the lifetime risk of sight-threatening complications after BKPro implantation, a longer follow-up period should provide outcomes that are more realistic. In this review, the authors examined only the results of publications with an average of at least 2 years of follow-up. The overall intermediate to long-term visual outcomes and retention rate in BKPro seem to be favorable. However, autoimmune diseases and cicatrizing conditions continue to show a higher incidence of postoperative complications that require further management.

show abstract

Section: Future Of Bkpromentioning

confidence: 99%